Predictors of Long-Term Temporomandibular Disorder Pain Intensity: An 8-Year Cohort Study

Aims: To investigate, in individuals with pain-related temporomandibular disorder (TMD), the association of long-term pain intensity with baseline health-related quality of life (HRQoL) and jaw functional limitation. Methods: Of 513 cases with baseline pain-related TMD (masticatory muscle and/or temporomandibular joint [TMJ] pain), 273 were reevaluated after 8 years, and 258 of them had complete baseline data for Jaw Functional Limitation Scale (JFLS) scores and HRQoL measured by the Physical Component Summary (PCS) and Mental Component Summary (MCS) scores of the 12-item Short Form Health Survey and follow-up data for Characteristic Pain Intensity (CPI) from the Graded Chronic Pain Scale. Secondary analyses of existing data quantified the effects of primary (PCS, MCS) and secondary (JFLS) predictors on follow-up CPI by using multivariable linear regression. Sensitivity analyses considered differences between the included participants (n = 258) and those who were not included (n = 255) by using inverse probability weighting. Interactions of baseline predictors with age, sex, and baseline CPI were evaluated using multivariable linear regression. Results: The score for baseline PCS, but not MCS or JFLS, was associated with follow-up CPI (P = .012). One standard deviation (SD = 9.0)–higher baseline PCS score predicted an overall 3.2-point–lower follow-up CPI (95% confidence interval –5.8 to –0.7) after adjusting for age, sex, MCS, JFLS, and baseline CPI scores. However, the effect of PCS score was not uniform: the association between PCS and follow-up CPI scores was statistically significant for participants with baseline CPI ≥ 51.3/100 and clinically significant for participants with baseline CPI ≥ 68.7/100. Adjustment for TMD treatments and sensitivity analyses had negligible effect. Conclusion: In participants with moderate to severe baseline TMD pain intensity, higher baseline physical HRQoL predicted lower TMD pain intensity at 8 years follow-up. PCS score could contribute to a multifactorial long-term TMD pain prediction model.

chronic pain;epidemiology;facial pain;quality of life;temporomandibular disorders

1.Okeson JP, de Kanter RJ. Temporomandibular disorders in the medical practice. J Fam Pract 1996;43:347–356.

2.LeResche L. Epidemiology of temporomandibular disorders: Implications for the investigation of etiologic factors. Crit Rev Oral Biol Med 1997;8:291–305.

3.National Institute of Dental and Craniofacial Research. Facial pain. http://www.nidcr.nih.gov/DataStatistics/FindDataByTopic/FacialPain/. Accessed 19 October 2017.

4.NIH Medline Plus. Chronic pain: Symptoms, diagnosis, and treatment. https://www.nlm.nih.gov/medlineplus/magazine/issues/spring11/articles/spring11pg5-6.html. Accessed 19 October 2017.

5.Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the sever-ity of chronic pain. Pain 1992;50:133–149.

6.Quartana PJ, Buenaver LF, Edwards RR, Klick B, Haythornthwaite JA, Smith MT. Pain catastrophizing and salivary cortisol responses to laboratory pain testing in temporomandib-ular disorder and healthy participants. J Pain 2010;11:186–194.

7.Johnson J, Johansson M, Rydén A, Houltz E, Finizia C. The impact of trismus on health-related quality of life and mental health. Head Neck 2015;37:1672–1679.

8.Dahlström L, Carlsson GE. Temporomandibular disorders and oral health-related quality of life. A systematic review. Acta Odontol Scand 2010;68:80–85.

9.De Leeuw R, Bertoli E, Schmidt JE, Carlson CR. Prevalence of traumatic stressors in patients with temporomandibular disor-ders. J Oral Maxillofac Surg 2005;63:42–50.

10.Epker J, Gatchel RJ. Coping profile differences in the biopsy-chosocial functioning of patients with temporomandibular dis-order. Psychosom Med 2000;62:69–75.

11.Zakrzewska JM. Multi-dimensionality of chronic pain of the oral cavity and face. J Headache Pain 2013;14:37.

12.Velly AM, Look JO, Carlson C, et al. The effect of catastroph-izing and depression on chronic pain—A prospective cohort study of temporomandibular muscle and joint pain disorders. Pain 2011;152:2377–2383.

13.McBeth J, Macfarlane GJ, Benjamin S, Silman AJ. Features of somatization predict the onset of chronic widespread pain: Results of a large population-based study. Arthritis Rheum 2001;44:940–946.

14.Lacey RJ, Lewis M, Sim J. Piecework, musculoskeletal pain and the impact of workplace psychosocial factors. Occup Med (Lond) 2007;57:430–437.

15.Linton SJ. A review of psychological risk factors in back and neck pain. Spine (Phila Pa 1976) 2000;25:1148–1156.

16.Melloh M, Elfering A, Egli Presland C, et al. Identification of prognostic factors for chronicity in patients with low back pain: A review of screening instruments. Int Orthop 2009;33:301–313.

17.Walton DM, Carroll LJ, Kasch H, et al. An overview of system-atic reviews on prognostic factors in neck pain: Results from the International Collaboration on Neck Pain (ICON) project. Open Orthop J 2013;7:494–505.

18. Zakrzewska JM. Differential diagnosis of facial pain and guide-lines for management. Br J Anaesth 2013;111:95–104.

19.Sanders AE, Slade GD, Bair E, et al. General health sta-tus and incidence of first-onset temporomandibular disor-der: The OPPERA prospective cohort study. J Pain 2013; 14(suppl):T51–T62.

20.Fillingim RB, Ohrbach R, Greenspan JD, et al. Psychological factors associated with development of TMD: The OPPERA prospective cohort study. J Pain 2013;14(suppl):T75–T90.

21.Fillingim RB, Ohrbach R, Greenspan JD, et al. Potential psy-chosocial risk factors for chronic TMD: Descriptive data and empirically identified domains from the OPPERA case-control study. J Pain 2011;12(suppl):T46–T60.

22.Aggarwal VR, Macfarlane GJ, Farragher TM, McBeth J. Risk factors for onset of chronic oro-facial pain—Results of the North Cheshire oro-facial pain prospective population study. Pain 2010;149:354–359.

23.Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF. Migraine headache disability and health-related quality-of-life: A population-based case-control study from en-gland. Cephalalgia 2003;23:441–450.

24.Picavet HS, Hoeymans N. Health related quality of life in multi-ple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study. Ann Rheum Dis 2004;63:723–729.

25.Salaffi F, De Angelis R, Stancati A, Grassi W, Marche Pain, Prevalence Investigation Group (MAPPING) study. Health-related quality of life in multiple musculoskeletal conditions: A cross-sectional population based epidemiological study. II. The MAPPING study. Clin Exp Rheumatol 2005;23:829–839.

26.Tjakkes GH, Reinders JJ, Tenvergert EM, Stegenga B. TMD pain: The effect on health related quality of life and the influ-ence of pain duration. Health Qual Life Outcomes 2010;8:46.

27.Barros Vde M, Seraidarian PI, Côrtes MI, de Paula LV. The impact of orofacial pain on the quality of life of patients with temporomandibular disorder. J Orofac Pain 2009;23:28–37.

28.Optum. SF-12v2 Health Survey. https://www.optum.com/optum-outcomes/what-we-do/health-surveys/sf-12v2-health-survey.html. Accessed 24 October 2017.

29.Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: Construction of scales and preliminary tests of reliabil-ity and validity. Med Care 1996;34:220–233.

30.Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item se-lection. Med Care 1992;30:473–483.

31.Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF. Migraine, quality of life, and depression: A popula-tion-based case-control study. Neurology 2000;55:629–635.

32.Mas AJ, Carmona L, Valverde M, Ribas B, EPISER Study Group. Prevalence and impact of fibromyalgia on function and quality of life in individuals from the general population: Results from a nationwide study in Spain. Clin Exp Rheumatol 2008;26:519–526.

33.Cheak-Zamora NC, Wyrwich KW, McBride TD. Reliability and validity of the SF-12v2 in the medical expenditure panel survey. Qual Life Res 2009;18:727–735.

34.Bair E, Ohrbach R, Fillingim RB, et al. Multivariable modeling of phenotypic risk factors for first-onset TMD: The OPPERA prospective cohort study. J Pain 2013;14(suppl):T102–T115.

35.Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9–19.

36.Ohrbach R, Larsson P, List T. The jaw functional limitation scale: Development, reliability, and validity of 8-item and 20-item versions. J Orofac Pain 2008;22:219–230.

37.Ohrbach R, Fillingim RB, Mulkey F, et al. Clinical findings and pain symptoms as potential risk factors for chronic TMD: Descriptive data and empirically identified domains from the OPPERA case-control study. J Pain 2011;12(suppl):T27–T45.

38.Schiffman EL, Truelove EL, Ohrbach R, et al The Research Diagnostic Criteria for Temporomandibular Disorders. I: Overview and methodology for assessment of validity. J Orofac Pain 2010;24:7–24.

39.Schiffman EL, Ahmad M, Hollender L, et al. Longitudinal sta-bility of common TMJ structural disorders. J Dent Res 2017; 96:270–276.

40.Schiffman E, Ohrbach R, Truelove E, et al. Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: Recommendations of the International RDC/TMD Consortium Network and Orofacial Pain Special Interest Group. J Oral Facial Pain Headache 2014;28:6–27.

41.Schiffman EL, Ohrbach R, Truelove EL, et al. The Research Diagnostic Criteria for Temporomandibular Disorders. V: Methods used to establish and validate revised Axis I diagnos-tic algorithms. J Orofac Pain 2010;24:63–78.

42.Ohrbach R, Granger C, List T, Dworkin S. Preliminary devel-opment and validation of the jaw functional limitation scale. Community Dent Oral Epidemiol 2008;36:228–236.

43.Ohrbach R, Turner JA, Sherman JJ, et al. The Research Diagnostic Criteria for Temporomandibular Disorders. IV: Evaluation of psychometric properties of the Axis II measures. J Orofac Pain 2010;24:48–62.

44.EuroQol Group. EuroQol—A new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208.

45.Seaman SR, White IR. Review of inverse probability weighting for dealing with missing data. Stat Methods Med Res 2013; 22:278–295.

46.Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clin-ical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105–121.

47.Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11- point numerical pain rating scale. Pain 2001;94:149–158.

48.Von Korff M. Assessment of chronic pain in epidemiolog-ical and health services research: Epirical bases and new directions. In: Turk DC, Melzack R (eds). Handbook of Pain Assessment, ed 3. New York: Guilford, 2011:455–471.

49.Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD state-ment for reporting studies of diagnostic accuracy: Explanation and elaboration. Ann Intern Med 2003;138:W1–W12.